Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE)


Creative Commons License

Hermans L. E., Svicher V., Pas S. D., Salpini R., Alvarez M., Ben Ari Z., ...Daha Fazla

JOURNAL OF INFECTIOUS DISEASES, cilt.213, sa.1, ss.39-48, 2016 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 213 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1093/infdis/jiv363
  • Dergi Adı: JOURNAL OF INFECTIOUS DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.39-48
  • Anahtar Kelimeler: antiviral drug resistance, genotypic resistance testing, hepatitis B virus, nucleos(t)ide analogs, COST-EFFECTIVENESS, REDUCED ANTIGENICITY, LAMIVUDINE TREATMENT, POLYMERASE GENE, PRIOR EXPOSURE, ENTECAVIR, MUTATIONS, TENOFOVIR, HBV, CONSEQUENCE
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe.